Session 118 - 12th CROI

Home

Session 118 Poster Abstracts
Drug Resistance and Viral Fitness
Thursday, 1:30 - 3:30 pm
Hall A

685	Recombination and Reversion Affect HIV-1 Fitness in Peripheral Blood Mononuclear Cells that Express CXCR4 Sarah Koch*¹, C Gavegnano¹, S Pomeroy¹, A Lowe¹, S Rose¹, J Sleasman², and M Goodenow¹ ¹Univ of Florida, Gainesville, USA and ²Univ of South Florida, St Petersburg, USA
686	Fitness Interactions with Positive Epistasis Prevail among Drug Treatment-associated Mutations Sebastian Bonhoeffer*¹, L Crooks¹, C Chappey², N Parkin², J Whitcomb², and C Petropoulos² ¹ETH Zurich, Switzerland and ²ViroLogic, Inc, South San Francisco, CA, USA
687	Enfuvirtide Resistance Mutations: Effect on HIV Envelope Function, Entry Inhibition, and Neutralization Jacqueline Reeves*, F H Lee, J Miamidian, C Jabara, M Juntilla, and R Doms Univ of Pennsylvania, Philadelphia, USA
688	The Efavirenz-resistant Reverse Transcriptase Mutants G190S and G190A Demonstrate Reductions in RNase Activity that Correlate with Reductions in HIV-1 Replication Fitness Jiong Wang*, C Dykes, R Domaoal, C Koval, R Bambara, and L Demeter Univ of Rochester, NY, USA
689	Impaired Intracellular Gag Trafficking and Viral Assembly in Protease Inhibitor Resistant HIV-1: New Mechanism of Viral Fitness Reduction in Drug Resistant Viruses Lay Myint*, Y Tomita, M Matsuda, M Nishizawa, H Miura, H Sato, N Yamamoto, and W Sugiura Natl Inst of Infectious Diseases, Tokyo, Japan
690	Evaluation of a Multiple Cycle, Recombinant Virus, Growth Competition Assay that Uses Flow Cytometry to Measure Replication Fitness of HIV in vitro Carrie Dykes*¹, J Wang¹, X Jin¹, V Planelles², D An³, A Tallo¹, Y Huang¹, H Wu¹, and L Demeter¹ ¹Univ of Rochester Sch of Med and Dentistry, NY, USA; ²Univ of Utah Sch of Med, Salt Lake City, USA; and ³Univ of California, Los Angeles, AIDS Inst, USA
691	Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Chronically HIV-1-infected Patients Javier Martinez-Picado*¹, T Wrin², S Frost³, B Clotet¹, L Ruiz¹, A Leigh Brown⁴, C Petropoulos², and N Parkin² ¹IrsiCaixa Fndn, Hosp Germans Trias I Pujol, Univ Autonoma de Barcelona, Spain; ²ViroLogic, Inc, South San Francisco, CA, USA; ³Univ of California, San Diego, USA; and ⁴Univ of Edinburgh, Scotland
692	HIV-1 Replication Capacity in HAART-failing Patients Predicts Virologic and Immunologic Responses when Accounting for Viral Susceptibility to the Salvage Regimen: Results from the Argenta Trial Andrea De Luca*¹, M Bates², S Di Giambenedetto¹, A Cingolani¹, E Coakley², C Petropoulos², R Cauda¹, and J Schapiro^3,4 ¹Catholic Univ, Rome, Italy; ²ViroLogic, Inc, South San Francisco, CA, USA; ³Sheba Med Ctr, Tel Aviv, Israel; and ⁴Stanford Univ Med Ctr, CA, USA